Serotyping: why, when, and how to assess your AAV therapeutic to get it approved

When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved.

As part of the CQA assessment, you need to make sure your vector is intact, that its serotype — or identity — is correct, and that your vector preps remain stable.  

In this video, learn why and when serotyping impacts AAV vector development. Discover how to assess your vector serotype so you can improve processes, monitor vector quality, and produce a more potent and effective AAV therapeutic.

Join this discussion with Léa Valla and Dr. Stefanie Kall,  AAV Applications Team at NanoTemper Technologies.

 

 

Previous Article
5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved
5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved

As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV the...

Up next
8 Gene Therapy conferences you should attend in 2022
8 Gene Therapy conferences you should attend in 2022

With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important ...

[New] Prometheus Panta with SLS

Build effective AAV vectors for gene therapy with
high-quality stability profiling data

Learn more